Business Context and Reporting Period
This Form 8-K/A filing by Ra Medical Systems, Inc. (trading symbol: RMED) reports on events occurring on October 12, 2020, specifically the Company's Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes, board appointments, and the adjournment of a specific proposal regarding a reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting results rather than financial performance metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 9,000,000.
- Board Appointments: Joan Stafslien was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, effective October 12, 2020. Her annual compensation for these roles is set at $14,500.
- Director Elections: Martin Colombatto and Joan Stafslien were re-elected as Class II directors.
- Accounting Firm Ratification: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, was ratified.
- Reverse Stock Split Adjournment: Proposal 3, seeking to approve a reverse stock split (ratio between 1-for-25 and 1-for-75), failed to pass due to insufficient votes. The meeting was adjourned to allow additional time for voting.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on business outlook. However, it notes that the reconvened Annual Meeting will be held virtually on November 2, 2020, due to public health concerns arising from the COVID-19 pandemic. The primary contingency is the pending vote on the reverse stock split at the reconvened meeting.
Investor Verification Checklist
- Verify the outcome of the reverse stock split proposal at the reconvened meeting on November 2, 2020.
- Review the definitive proxy statement filed on August 28, 2020, for full details on the amended Equity Incentive Plan.
- Confirm the final composition of the Board of Directors and committee assignments following the October 12 appointments.
- Monitor future filings for any financial updates, as this 8-K does not contain current period financial results.